The integration of SIRI with emerging immunologic biomarkers—such as PD-L1 expression, tumor-infiltrating lymphocytes, and cytokine profiles—could further elucidate the interplay between systemic inflammation and immune suppression in PDAC. This evidence concerns the gene CD274 and neoplasm.